Gate’s “Molecular Gates” sound like a sci-fi concept, but let’s be real: it’s just another way to target proteins that no one else could be bothered to touch. The idea is simple-why stop at easy targets when you can complicate your life? It’s like ordering a salad but then asking for extra ranch, pretzels, and a side of existential dread. Lilly’s paying for the ranch, the pretzels, and the dread. All in one bite.
The company’s Artificial Intelligence Platform, that most modern of alchemical tools, has worked wonders on the balance sheet. One might almost believe the U.S. government and its corporate sycophants have discovered a new form of currency more valuable than gold. Revenue figures for the second quarter read like the ledger of a Victorian railway baron: $733 million in U.S. revenue, with the commercial segment tripping along at 93% year-over-year growth. It is a performance that would make Dickens’ Mr. Bumble weep into his corned beef.
By 2025, the corporation seemingly executes its strategy with the cold precision of a bureaucrat, layering interfaces upon interfaces, each more labyrinthine than the last-web, Android, iOS-each detaching the user further from a straightforward experience while simultaneously coaxing them toward a singular, indiscernible goal: transaction. A microcosm of control, the interface shifts like a Dadaist’s dream-features moved, repositioned, concealed in menus that seem designed not for utility but for a perpetually delayed revelation-an exercise in patience or despair, depending on one’s state of mind.
By Friday’s early light, the stock’s week-to-date ascent of 11% stood as a testament to the alchemy of numbers and narrative. Yet beneath the surface, one senses the uneasy marriage of tradition and technology-a union born of necessity rather than affection.
Yet, as any true Discworld investor knows, chaos often breeds opportunity. Let us explore how one peculiar factor might yet turn this “crisis” into a “golden opportunity”-assuming, of course, the cocoa gods are in a charitable mood.
Enter stage left: two stocks that, with a mere $1,000, could turn into the seeds of a fortune, long after the current year’s fireworks have faded-ASML Holding and Alphabet. Both are promising, in their own peculiar ways, to grow along with the tech landscape, provided you have patience, a bit of nerve, and the willingness to wait out the inevitable squalls.
The analysts, those modern-day oracles of the financial world, have thrown Joby into chaos. H.C. Wainwright, in a move as dramatic as a Shakespearean villain’s monologue, downgraded the stock from “buy” to “neutral,” citing valuation concerns. Meanwhile, Canaccord managed the impressive feat of both downgrading the stock to “hold” and raising its price target to $17-a financial tightrope act that would leave Cirque du Soleil envious. The stock closed at $17.25, a figure that now feels as meaningful as a prophecy from a teacup-reading llama.
And Curaleaf, Curaleaf (CURLF) – a company name that sounds like a cough drop – predictably, reported a loss for the quarter. After the bell. Of course. Like they were trying to hide it. A $53 million loss. It’s not *much* worse than last year, they’re saying. Not much worse! As if that’s a selling point. “Hey, we’re still losing a fortune, but it’s a slightly more *manageable* fortune!” What is that? It’s just… a loss.
Act the First: The Analyst’s Flattering Mirror.
Our farce commences with Monsignor Gong of UBS, who, like some benevolent but deluded patron of the arts, declares Pony AI worthy of a princely $20-a most optimistic appraisal for a company whose primary achievement hitherto is piloting empty carriages through Beijing’s thoroughfares (albeit without drivers, which is something, if one ignores the occasional pedestrian’s startled leap).
DNUT”>[stock_chart symbol="NASDAQ:DNUT" f_id="344778" language="en"]